1. Home
  2. XRTX

XRTX

XORTX Therapeutics Inc.

Logo XORTX Therapeutics Inc.

Health Care

Pharmaceuticals and Biotechnology

Nasdaq

as 04-16-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Founded: 2011 Country:
Canada
Canada
Employees: N/A City: N/A
Market Cap: 10.2M IPO Year: N/A
Target Price: $14.00 AVG Volume (30 days): 49.0K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -4.27 EPS Growth: N/A
52 Week Low/High: $1.98 - $72.09 Next Earning Date: 05-14-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: